240 related articles for article (PubMed ID: 22131878)
21. A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.
Sempere LF; Gunn JR; Korc M
Cancer Biol Ther; 2011 Aug; 12(3):198-207. PubMed ID: 21613822
[TBL] [Abstract][Full Text] [Related]
22. Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib.
Poteet E; Liu D; Liang Z; Van Buren G; Chen C; Yao Q
PLoS One; 2019; 14(3):e0213294. PubMed ID: 30921351
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
24. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Bean J; Brennan C; Shih JY; Riely G; Viale A; Wang L; Chitale D; Motoi N; Szoke J; Broderick S; Balak M; Chang WC; Yu CJ; Gazdar A; Pass H; Rusch V; Gerald W; Huang SF; Yang PC; Miller V; Ladanyi M; Yang CH; Pao W
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20932-7. PubMed ID: 18093943
[TBL] [Abstract][Full Text] [Related]
25. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
26. Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival.
Leung PY; Chen W; Sari AN; Sitaram P; Wu PK; Tsai S; Park JI
World J Gastroenterol; 2024 Feb; 30(7):714-727. PubMed ID: 38515951
[TBL] [Abstract][Full Text] [Related]
27. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.
Banno E; Togashi Y; de Velasco MA; Mizukami T; Nakamura Y; Terashima M; Sakai K; Fujita Y; Kamata K; Kitano M; Kudo M; Nishio K
Int J Oncol; 2017 Jun; 50(6):2049-2058. PubMed ID: 28440469
[TBL] [Abstract][Full Text] [Related]
29. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
[TBL] [Abstract][Full Text] [Related]
30. Tumor resensitization to erlotinib following brief substitution of cetuximab.
Epstein RJ; Leung TW
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1111-2. PubMed ID: 18283460
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.
Slee RB; Grimes BR; Bansal R; Gore J; Blackburn C; Brown L; Gasaway R; Jeong J; Victorino J; March KL; Colombo R; Herbert BS; Korc M
Mol Cancer Ther; 2014 Feb; 13(2):307-315. PubMed ID: 24282275
[TBL] [Abstract][Full Text] [Related]
32. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Zhang X; Belkina N; Jacob HK; Maity T; Biswas R; Venugopalan A; Shaw PG; Kim MS; Chaerkady R; Pandey A; Guha U
Proteomics; 2015 Jan; 15(2-3):340-55. PubMed ID: 25404012
[TBL] [Abstract][Full Text] [Related]
33. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Buck E; Eyzaguirre A; Brown E; Petti F; McCormack S; Haley JD; Iwata KK; Gibson NW; Griffin G
Mol Cancer Ther; 2006 Nov; 5(11):2676-84. PubMed ID: 17121914
[TBL] [Abstract][Full Text] [Related]
34. [Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy].
Shi C; Han B; Gu A; Xiong L; Shen J
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):529-33. PubMed ID: 21645458
[TBL] [Abstract][Full Text] [Related]
35. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
[TBL] [Abstract][Full Text] [Related]
36. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
37. ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?
Landgraf R
Cancer Biol Ther; 2010 Sep; 10(6):564-6. PubMed ID: 20676043
[No Abstract] [Full Text] [Related]
38. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.
Renouf DJ; Tang PA; Hedley D; Chen E; Kamel-Reid S; Tsao MS; Tran-Thanh D; Gill S; Dhani N; Au HJ; Wang L; Moore MJ
Eur J Cancer; 2014 Jul; 50(11):1909-15. PubMed ID: 24857345
[TBL] [Abstract][Full Text] [Related]
39. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
40. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.
Griffero F; Daga A; Marubbi D; Capra MC; Melotti A; Pattarozzi A; Gatti M; Bajetto A; Porcile C; Barbieri F; Favoni RE; Lo Casto M; Zona G; Spaziante R; Florio T; Corte G
J Biol Chem; 2009 Mar; 284(11):7138-48. PubMed ID: 19147502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
